Overview

Dolutegravir Expanded Access Study

Status:
Completed
Trial end date:
2016-09-23
Target enrollment:
Participant gender:
Summary
ING114916 is an open-label, multi-center, expanded access (EAP) study
Phase:
N/A
Details
Lead Sponsor:
ViiV Healthcare
Collaborator:
GlaxoSmithKline
Treatments:
Dolutegravir